Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: frovatriptan succinate

« Back to Dashboard
Frovatriptan succinate is the generic ingredient in two branded drugs marketed by Endo Pharms and Mylan Pharms Inc, and is included in two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has fifty-four patent family members in thirty-three countries.

There are three drug master file entries for frovatriptan succinate. Four suppliers are listed for this compound.

Summary for Generic Name: frovatriptan succinate

Tradenames:2
Patents:2
Applicants:2
NDAs:2
Drug Master File Entries: see list3
Suppliers / Packaging: see list5
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: frovatriptan succinate

Clinical Trials for: frovatriptan succinate

Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine
Status: Completed Condition: Migraine

Frovatriptan as a Transitional Therapy in Medication Overuse Headache
Status: Recruiting Condition: Medication Overuse Headache; Analgesic Overuse Headache

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals
Status: Completed Condition: Migraines; Bleeding; Spotting

Frovatriptan and Menstrual Migraine
Status: Terminated Condition: Frovatriptan; Menstrual Migraine

A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting
Status: Completed Condition: Migraine

Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine
Status: Completed Condition: Menstrual Migraine (MM) Headaches

Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches
Status: Completed Condition: Migraine

A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
Status: Completed Condition: Migraine

A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine
Status: Completed Condition: Migraine

Renal Denervation by Allegro System in Patients With Resistant Hypertension
Status: Recruiting Condition: Renal Denervation; Resistant Hypertension; Standard Medication

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 2001RXYes5,827,871<disabled><disabled>
Mylan Pharms Inc
FROVATRIPTAN SUCCINATE
frovatriptan succinate
TABLET;ORAL202931-001Aug 28, 2014RXNo<disabled><disabled>
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 2001RXYes5,464,864<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: frovatriptan succinate

Country Document Number Publication Date
Slovakia280905Sep 12, 2000
Slovakia280906Sep 12, 2000
United Kingdom9113802Aug 14, 1991
JapanH06508827Oct 06, 1994
Czech Republic282083May 14, 1997
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc